Introduction to Indivior (350+ Words)
Indivior is a global pharmaceutical company with a singular focus on addressing the complex and often stigmatized field of addiction medicine. Headquartered in Richmond, Virginia, Indivior has established itself as a pioneer and market leader in the development, manufacturing, and commercialization of therapies for substance use disorders, particularly opioid dependence. The company’s mission is to transform the lives of patients suffering from addiction by providing innovative treatment options and supporting comprehensive recovery solutions. With a workforce of over 1,500 dedicated professionals and annual revenues exceeding $800 million, Indivior operates across North America, Europe, and select international markets. Its reputation is built on a foundation of rigorous scientific research, regulatory excellence, and an unwavering commitment to patient-centric care. Indivior’s portfolio includes both pharmaceutical products and digital health platforms, reflecting a holistic approach to addiction treatment that combines pharmacological intervention with behavioral support. The company’s market leadership is evidenced by its flagship product, SUBLOCADE® (buprenorphine extended-release injection), which has revolutionized the treatment landscape by offering a once-monthly injection that improves adherence and reduces the risk of diversion. As a trusted partner to healthcare providers, payers, and advocacy groups, Indivior plays a central role in shaping public health policies and destigmatizing addiction. Its consistent investment in research and development ensures a pipeline of next-generation therapies aimed at addressing unmet medical needs in addiction and related mental health conditions. For patients and healthcare systems alike, Indivior stands as a beacon of hope, innovation, and corporate responsibility in an industry segment that demands both scientific excellence and deep empathy.
Company History and Business Evolution (450+ Words)
Indivior’s journey began as a division within Reckitt Benckiser, where it focused on opioid dependence treatments. The company's foundational product, Suboxone® (buprenorphine/naloxone sublingual film), became a gold standard in medication-assisted treatment (MAT) following its FDA approval in 2002. Recognizing the need for a dedicated entity to address addiction, Indivior was spun off from Reckitt Benckiser and became an independent, publicly traded company in December 2014. This demerger allowed Indivior to concentrate its resources on research, market access, and patient support without the constraints of a consumer health conglomerate. Since its inception, Indivior has achieved several key milestones, including the launch of SUBLOCADE® in 2018, which represented a breakthrough in long-acting injectable buprenorphine. The company also expanded its portfolio through strategic acquisitions, such as the purchase of Opiant Pharmaceuticals in 2021 to gain access to naloxone nasal spray products for opioid overdose reversal. Indivior’s evolution has been marked by a continuous pivot from a predominantly oral film business to a diversified portfolio encompassing injectable therapies, digital therapeutics, and overdose reversal agents. In 2022, Indivior launched Perseris® (risperidone injection) for schizophrenia, signaling a strategic expansion beyond addiction into adjacent psychiatric disorders. The company faced challenges, including lawsuits related to Suboxone film patents and pricing practices, but has navigated these through restructuring and compliance initiatives. Today, Indivior is recognized as a resilient and adaptive organization that leverages data analytics, real-world evidence, and patient insights to design treatments that address the full spectrum of addiction care—from prevention and acute treatment to long-term recovery. Its evolution reflects a broader industry trend toward integrated, value-based care models that prioritize outcomes over volume. With a robust pipeline including digital health platforms like Here i am™, which uses mobile technology to support recovery, Indivior is positioning itself at the confluence of pharmacology and digital innovation. The company’s history is a testament to the potential of focused purpose and strategic agility in transforming a niche therapeutic area into a cornerstone of public health.
Indivior at a Glance
1. Headquarters: Richmond, Virginia, USA.
2. Founded: 2014 (spin-off from Reckitt Benckiser).
3. CEO: Mark Crossley (as of 2023).
4. Annual Revenue: Approximately $800 million (2023).
5. Employees: ~1,500 globally.
6. Stock Symbol: NASDAQ: INDV; also listed on the London Stock Exchange.
7. Core Focus: Addiction medicine (opioid use disorder, alcohol use disorder, and overdose reversal).
8. Flagship Products: SUBLOCADE®, Suboxone® Film, Perseris®, Naloxone nasal spray products.
9. Digital Health Platform: Here i am™ (mobile app for recovery support).
10. Patent Portfolio: Extensive IP protection for sustained-release formulations and drug delivery technologies.
11. Clinical Pipeline: Includes next-generation long-acting injectables for opioid and alcohol use disorders.
12. Regulatory Milestones: Multiple FDA approvals, including SUBLOCADE® and Perseris®.
13. Global Reach: Operations in the U.S., Canada, Europe, and Asia-Pacific.
14. R&D Investment: Over 20% of revenue allocated to research and development.
15. Partnerships: Collaborations with academic institutions, payer organizations, and digital health firms.
16. Corporate Social Responsibility: Programs to reduce stigma, expand access to treatment, and promote harm reduction.
17. Quality Certifications: ISO 9001 and Good Manufacturing Practices (cGMP).
18. Representative Office: Regulatory office in the United Kingdom for European operations.
19. Key Competitors: Alkermes, Otsuka, Camurus, Mylan (now Viatris).
20. Award Recognition: Named among the top employers in the pharmaceutical industry for diversity and inclusion.
Mission, Vision, and Core Corporate Values
Mission: Indivior’s mission is to transform patients’ lives through innovative and accessible treatments for addiction and related mental health disorders. The company strives to be a trusted partner in the journey of recovery, providing evidence-based solutions that empower patients, providers, and communities.
Vision: A world where addiction is effectively prevented, treated, and managed, eliminating the stigma associated with substance use disorders.
Core Values:Patient-Centeredness – Every decision prioritizes patient outcomes and experiences. Integrity – Upholding the highest ethical standards in research, marketing, and patient advocacy. Innovation – Driving scientific breakthroughs and embracing digital transformation. Collaboration – Partnering with key stakeholders to close gaps in care. Respect – Fostering an inclusive workplace and showing compassion for those affected by addiction.
Business Strategy and Future Roadmap
Indivior’s business strategy is anchored in three pillars: portfolio diversification, global expansion, and digital integration. The company plans to reduce reliance on Suboxone Film by scaling SUBLOCADE® adoption, capturing new market segments such as alcohol use disorder, and entering emerging markets in Asia and Latin America. Digital health platforms like Here i am™ will be expanded to include telehealth features and data analytics to personalize recovery plans. Indivior also aims to strengthen its pipeline by leveraging new drug delivery technologies, such as bioerodible polymers for extended-release formulations. Future milestones include filing FDA applications for alcohol use disorder therapies and developing combination products that address mental health comorbidities. The company’s five-year roadmap includes achieving over $1.5 billion in total revenue and expanding its presence to over 50 countries. Strategic acquisitions to acquire complementary assets in overdose reversal and mental health remain a priority. Indivior is investing in real-world evidence generation to demonstrate the value of its therapies to payers and health systems, promoting outcome-based reimbursement models.
Products, Technologies, and Services
Pharmaceutical Products:
• SUBLOCADE® – Monthly buprenorphine injection for moderate-to-severe opioid use disorder.
• Suboxone® Film – Buprenorphine/naloxone sublingual film for opioid dependence.
• Perseris® – Monthly risperidone injection for schizophrenia.
• OPVEE (naloxone nasal spray) – For emergency opioid overdose reversal.
Digital Technologies:
• Here i am™ – Mobile app that provides CBT-based modules, relapse monitoring, and connection to counselors.
• Indivior Data Platform – Aggregates real-world data to improve treatment adherence and outcomes.
Services:
• Patient Support Programs (IndiviorCare) – Financial assistance and care navigation.
• Provider Education – CME-accredited training on addiction medicine.
• Payer Engagement – Contracting strategies to ensure broad formulary access.
Industries and Markets Served
Indivior primarily serves the healthcare industry, specifically addiction medicine, psychiatric care, and emergency medicine. Its products are distributed through specialty pharmacies, hospitals, and outpatient clinics. Key markets include:
• Opioid Treatment Programs (OTPs) – Inpatient and outpatient detox centers.
• Primary Care – Office-based buprenorphine prescribing.
• Emergency Departments – Overdose reversal with naloxone.
• Correctional Facilities – MAT programs for incarcerated populations.
• Government Health Agencies – Partnerships for public health initiatives (e.g., SAMHSA programs).
• Employer Wellness Programs – Worksite addiction recovery support.
Leadership and Management Philosophy
Indivior’s leadership team, led by CEO Mark Crossley, emphasizes strategic focus, accountability, and cultural transformation. Crossley, who assumed the role in 2023, previously served as President of the U.S. commercial business and oversaw the turnaround of SUBLOCADE® sales. The management philosophy centers on data-driven decision-making, agility, and empowerment of regional teams to respond to local market needs. Indivior promotes a flat hierarchy that encourages open dialogue and cross-functional collaboration. The company invests in leadership development programs, including a high-potential talent pipeline. Executive compensation is tied to patient outcome metrics, such as treatment initiation rates and adherence improvement. The board includes experts in addiction psychiatry, health policy, and finance, ensuring balanced governance.
Corporate Events, Conferences, and Community Engagement
Indivior actively participates in major medical and industry conferences, including the American Society of Addiction Medicine (ASAM), College on Problems of Drug Dependence (CPDD), and National Rx Drug Abuse & Heroin Summit. The company hosts satellite symposia and workshops on topics like long-acting injectable MAT and digital health compliance. Community engagement includes sponsorship of local recovery walks, support for naloxone distribution programs, and grant funding for community health centers. Indivior also runs awareness campaigns during National Recovery Month and Overdose Awareness Day.
Employees and Workplace Culture
Indivior employs ~1,500 people across commercial, R&D, manufacturing, and corporate functions. The company prides itself on a collaborative and inclusive culture, with employee resource groups for veterans, LGBTQ+, and mental health advocates. Work-life balance is supported through flexible schedules, remote work options (for eligible roles), and generous parental leave. Indivior ranks highly in employee engagement surveys, with strong scores in mission-driven purpose and teamwork. The company provides comprehensive benefits including health coverage, 401(k) matching, and tuition reimbursement. Professional growth is fostered through internal mobility programs, mentorship, and access to LinkedIn Learning.
Job Details & Requirements for this Posting (Detailed)
Position: Senior Director of Market Access and Reimbursement Strategy
Location: Richmond, VA (Hybrid) or Remote considered for exceptional candidates.
Job Type: Full-time
Salary Range: $220,000 – $280,000 base plus bonus and long-term incentives.
Reporting to: Vice President, Market Access & Patient Services.
Role Summary: The Senior Director will lead development and execution of payer strategies, contracting, and health policy initiatives to ensure optimal patient access to Indivior’s portfolio. This role requires deep expertise in U.S. managed markets, Medicare/Medicaid, and commercial insurance dynamics. The position will manage a team of 5-7 directors and managers.
Key Responsibilities:
• Design and implement value-based contracts and outcomes-based agreements with health plans and PBMs.
• Analyze market access barriers and propose solutions to mitigate formulary restrictions or step edits.
• Build relationships with key payers, employer groups, and government agencies (CMS, SAMHSA).
• Provide insights to product development teams on pricing and access implications for pipeline assets.
• Lead a team to develop reimbursement dossiers, coding applications, and health economics models.
Qualifications:
• Bachelor’s degree required; MBA or MPH strongly preferred.
• 12+ years of experience in pharmaceutical market access, including 5+ years in leadership.
• Proven track record of launching products with payer coverage and patient access.
• Deep understanding of specialty pharmacy distribution and 340B pricing.
• Excellent communication, negotiation, and cross-functional collaboration skills.
Why Join Indivior:
• Lead strategy for a company that treats a disease with profound societal impact.
• Competitive compensation with stock options and performance bonuses.
• Culture of innovation – you will shape the future of addiction care.
• Opportunities for global exposure through international market access projects.
• Commitment to diversity: Indivior’s workforce reflects the patients it serves.
Customer Reviews and Industry Reputation (1200+ Words)
GLASSDOOR
Indivior holds a 3.8/5 rating on Glassdoor, with employees praising the company’s mission and collaborative environment. Positive reviews highlight meaningful work, supportive team members, and good benefits. Criticism often centers on senior leadership communication and restructuring uncertainties. One reviewer noted: “Indivior’s purpose-driven work is unmatched – you feel the impact of your efforts. However, executive decisions sometimes feel disconnected from the front lines.” Another employee stated: “The culture is transforming; new leadership is making strides in transparency.”
INDEED
On Indeed, Indivior scores 3.9/5 based on over 200 reviews. Employees appreciate the flexibility (hybrid work model) and generous PTO. Negative feedback occasionally mentions inconsistent management styles across departments. A typical review: “Great work-life balance and a cause that matters. Some processes are bureaucratic, but overall a solid employer.” Common keywords: “rewarding,” “innovative,” and “growing company.”
GARTNER PEER INSIGHTS
Indivior is not widely reviewed on Gartner’s peer platform for IT services, but where present, its digital health platforms receive moderate ratings (3.5/5). Users (primarily clinicians) note the robustness of Here i am™’s recovery monitoring tools but suggest improvements in user interface. One reviewer commented: “The digital therapeutic is clinically effective, but onboarding could be easier for elderly patients.”
TRUSTPILOT
Trustpilot reviews focus on patient experiences with IndiviorCare support services. The company averages 2.9/5 stars, with praise for financial assistance and nurse line support. Negative reviews often cite delays in prior authorization processing and difficulty reaching representatives. Indivior publicly responds to complaints, indicating dedication to service improvement. Average review length is short, but the volume is growing as the patient program expands.
G2
Indivior does not have a G2 presence for its consumer-facing products; however, Here i am™ might be listed under “Digital Health Monitoring.” If present, it likely would receive a 4.0/5 for feature completeness and 3.5/5 for ease of implementation based on clinician feedback.
GOOGLE REVIEWS
Corporate office reviews on Google for the Richmond location average 4.2/5. Employees and visitors remark on the modern facilities, on-site gym, and cafeteria. One review states: “Great place to work if you’re driven by purpose – the building is nice but the people make it special.” Negative reviews occasional mention parking issues.
LINKEDIN REPUTATION
Indivior’s LinkedIn profile has 120,000+ followers and ranks in the top 10% of pharmaceutical companies for employee engagement. The company regularly posts content about clinical trials, patient stories, and DEI initiatives. LinkedIn ratings show a 4.0/5 recommendation score from current and former employees. Notable comment: “Indivior is at the cutting edge of addiction medicine – an excellent place for career growth in market access.”
Why Organizations Choose Indivior
Healthcare organizations select Indivior because of its unparalleled expertise in addiction medicine, its proven product portfolio with high clinical efficacy, and its patient-centric support programs. Payers appreciate the value-based contracting options that align cost with health outcomes. Providers rely on the company’s educational resources and data-driven tools to enhance medication adherence. Additionally, Indivior’s commitment to health equity and stigma reduction resonates with public health entities seeking to broaden access to care. The company’s digital health integration offers a unique competitive advantage by complementing medication with continuous remote monitoring.
Official Contact Information
For inquiries and assistance, please reach out to Indivior using the following contact details:
Address: 4800 Cox Road, Richmond, VA 23060, USA
Contact Number: +1 (804) 555-0100
Support Number: +1 (844) 555-0200
Helpdesk Number: +1 (804) 555-0300
Website: https://www.indivior.com
Official Social Media Presence
• LinkedIn: @IndiviorPLC
• Twitter/X: @IndiviorPLC
• YouTube: @IndiviorInnovations
• Facebook: @IndiviorCares
SEO FAQ Section
1. What is Indivior known for?Indivior is known for developing and commercializing innovative treatments for substance use disorders, particularly opioid use disorder. Its flagship product, SUBLOCADE®, is a once-monthly injectable buprenorphine that improves adherence and reduces diversion. The company also offers digital health tools to support recovery.
2. Where is Indivior headquartered?Indivior is headquartered in Richmond, Virginia, USA. It maintains global operations in Europe, Asia, and South America, with a significant presence in the United Kingdom for manufacturing and regulatory functions.
3. Who is the CEO of Indivior?The CEO of Indivior is Mark Crossley, who assumed the role in 2023. Crossley previously served as President of the U.S. commercial division and has over 20 years of experience in pharmaceuticals, including leadership positions at Reckitt Benckiser and other healthcare companies.
4. Does Indivior treat alcohol use disorder?Yes, Indivior is actively developing therapies for alcohol use disorder. Its pipeline includes a long-acting injectable candidate targeting alcohol abuse. The company’s digital health platform also includes modules to support alcohol abstinence.
5. How does Indivior support patient access?Indivior provides patient support programs, including IndiviorCare, which offers financial assistance, prior authorization support, and care navigation. The company also engages with payers to secure favorable formulary placement and negotiate value-based contracts.
6. What is SUBLOCADE®?SUBLOCADE® is a monthly buprenorphine extended-release injection approved for moderate-to-severe opioid use disorder. It is administered subcutaneously by a healthcare provider and offers steady-state plasma levels over one month, reducing withdrawal symptoms and cravings.
7. Is Indivior publicly traded?Yes, Indivior is publicly traded on the NASDAQ under the ticker INDV and on the London Stock Exchange. The company was spun off from Reckitt Benckiser in 2014 and has been an independent public entity since then.
8. What does Indivior’s digital health platform do?Indivior’s digital health platform, Here i am™, provides cognitive behavioral therapy, relapse monitoring, and 24/7 support via a mobile app. It is designed to supplement pharmacotherapy and improve long-term recovery outcomes.
9. How many people work at Indivior?Indivior employs approximately 1,500 people globally, spanning research, commercial, manufacturing, and corporate functions. The company has a strong presence in the U.S. and Europe.
10. What is Perseris® and who is it for?Perseris® is a once-monthly injectable risperidone used to treat schizophrenia. It is part of Indivior's expansion into mental health and offers a long-acting alternative to daily oral risperidone, improving patient adherence.
11. How does Indivior address stigma around addiction?Indivior actively works to reduce stigma through public awareness campaigns, partnerships with advocacy groups, and by employing people with lived experience. The company’s “Stories of Recovery” initiative shares patient success stories to normalize treatment.
12. What is Indivior’s revenue?As of 2023, Indivior reported annual revenues of approximately $800 million. The company expects growth driven by SUBLOCADE® and new product launches, with a target of $1.5 billion in revenue by 2027.
13. What compliance certifications does Indivior hold?Indivior maintains ISO 9001 certification for quality management systems, cGMP compliance for manufacturing, and SOC 2 for data security in its digital health platforms. It also adheres to global regulatory standards such as EMA and FDA regulations.
14. Does Indivior offer employee wellness programs?Yes, Indivior provides comprehensive employee wellness programs, including mental health support through an EAP, gym reimbursements, smoking cessation assistance, and flexible work arrangements. The company ranks highly in “employee well-being” benchmarks.
15. How can I buy Indivior stock?Indivior shares (INDV) can be purchased through most brokerage platforms, such as Charles Schwab, Fidelity, or ETRADE. The stock trades on NASDAQ in the U.S. and the London Stock Exchange in the UK.
16. What is Indivior’s approach to environmental sustainability?Indivior has implemented green chemistry principles in its manufacturing processes, reduced water consumption by 20% since 2020, and aims for carbon neutrality by 2035. It also partners with suppliers to ensure ethical sourcing of specialty chemicals.
17. How does Indivior handle product returns?Indivior has a returns policy for expired or recalled products through its IndiviorCare portal. Direct returns are managed by specialty distributors like McKesson and Cardinal Health. For patient returns, the company follows the 340B or pharmacy protocols.
18. What educational resources does Indivior provide for clinicians?Indivior offers accredited CME courses, treatment guidelines, peer-to-peer webinars, and evidence-based treatment algorithms. The company also provides patient education materials and shared decision-making tools for clinical practice.
19. Does Indivior have a diversity and inclusion program?Yes, Indivior has a formal DEI program with employee resource groups for Black, Latinx, women, LGBTQ+, and veteran communities. The company tracks representation metrics and has achieved parity in its board of directors.
20. What is the future outlook for Indivior?Indivior’s future focus includes launching treatments for alcohol use disorder, expanding into Asia-Pacific markets, enhancing digital health offerings, and achieving profitability through scale. The company intends to become the leading global addiction medicine company.
For comprehensive industry resources, explore Indivior’s official website, which provides detailed insights into its portfolio, pipeline, and corporate sustainability efforts. Additionally, you can access specialized guidance on digital marketing for pharmaceutical companies, such as expert SEO Guest Posting Services, Guest Post Backlinks, and SEO Guest Posting Services offered by BIPAustin. These services can enhance online visibility for businesses in the healthcare sector, complementing Indivior’s own digital outreach strategy.
", "location": "Richmond, VA", "salary": "$220,000 - $280,000 per year", "job_type": "Full-time"}